How "Pharmaceutical Headlines" Multinational Pharmaceutical Companies Play the Internet Plus

(2020/11/18) Baishi Meishi Guibao's $13.1 billion cash acquisition of MyoKardia; (Click on the title for the original article) Bristol Myers Squibb, BMS announced on November 17th that it had successfully completed its $13.1 billion all-cash acquisition of MyoKardia, Inc.
acquisition, MyoKardia's shares ceased trading on NASDAQ's Global Select Market and became a wholly owned subsidiary of BMS.
: Hypertrophotic obstructive cardiomyopathy is a chronic developing disease.
the era of large varieties of domestic vaccines has started! The current situation of vaccine industry development at home and abroad is analyzed and studied because of the use of vaccines, the flux disappears from the earth, polio is almost gone, measles, rubella, diphtheria and other infectious diseases have been effectively controlled.
addition, human life expectancy has increased significantly over the past half century, both because of the use of clean water and because of the spread of vaccines.
: The global vaccine market has created an oligopoly competitive landscape.
Novarma, Pfizer, Lilly high-profile into the market to see how pharmaceutical companies play the "Internet plus" China's Internet plus medicine high-gloss moment is coming.
, the out-of-hospital pharmaceutical market is expanding at a 10.8 percent compound annual rate between 2015 and 2019, while online sales are growing at a compound annual rate of 30.4 percent, according to the Frost Sullivan report.
25.8% of China's total retail sales of consumer goods in 2019 have been distributed online, while only 7.6% of out-of-hospital drug sales will be distributed online, and Frost Sullivan predicts that by 2030, 27.5% of medicines will be distributed online through off-the-cul-de-sham sales channels.
headlines: Multinational drug executives are starting to move to the Internet and healthcare platforms.
The Authoritative List: 10 start-ups worth watching in 2020! The American Chemical Society(ACS) website has released a list of 10 high-profile start-ups for 2020.
10 new start-ups on this year's list were carefully selected from more than 200 start-ups, according to C and EN, a company that has been selected.
they are not only revolutionary chemical technologies, but are also committed to solving important problems related to human life.
headlines: how start-ups are using chemical innovation for the benefit of humanity.
Medicine Rubik's Cube: MSI-H/dMMR Advanced Solid Tumors: How do each PD-1/PD-L1 perform? On November 16, 2020, Synaptic Pharmaceuticals announced a new drug listing application (KN035) for a recombinant humanized PD-L1 monometric antibody Nvolly monoantigen injection (KN035) in a strategic partnership with Corning Jerry Biopharmaceuticals and ThinkDi Pharmaceuticals (KN035) The NDA has been formally submitted to the National Drug Administration (NMPA) for the treatment of advanced colorectal cancer, stomach cancer and other mismatched repair functional defects (dMMR) advanced solid tumors for the treatment of microsatellite instability (MSI-H) that has failed in the past.
headline bacteria: a stone stirs up a thousand waves.